NCT06070532View on ClinicalTrials.gov

A Study of Human Allogeneic Bone-marrow-derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Aging Frailty

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

January 10, 2027

Conditions

Frailty

Interventions

BIOLOGICAL

Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)

100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion 100 million cells in approximately 30 min

Trial Locations (1)

Unknown

To be decided, Nassau

All Listed Sponsors

lead

Cellcolabs Clinical LTD.

INDUSTRY